If you have been reading about LC-MS/MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
== Arbeitsgebiete == Das Institut widmet sich der Grundlagenforschung auf dem Gebiet der weichen Materie, insbesondere von Polymeren. Ziel ist der Erkenntnisgewinn über Zusammenhänge von chemischer Struktur, physikalischen Eigenschaften und Funktion makromolekularer Materialien. Zu diesem Zweck ist die wissenschaftliche Arbeit des MPI-P nicht streng in Abteilungen, sondern fächerübergreifend organisiert. Die Hauptaktivitäten des Instituts können wie folgt zusammengefasst werden:
Synthetische makromolekulare Chemie Entwicklung neuer Synthesemethoden Herstellung von Polymeren mit unkonventioneller Struktur Entwicklung von Systemen selektiver Funktionalität, insbesondere von Polymeren, die Ladungen oder bestimmte Moleküle transportieren Supramolekulare Architekturen Erzeugung von Polymeren mit kolumnarer Struktur Systeme mit Aggregation über Wasserstoffbrücken hochverzweigte Makromoleküle Modellmembranen ultradünne Filme und Schichten definiert strukturierte organisch-anorganische Hybridsysteme, Oberflächenbeschichtungen mit Bio-Funktionalität Struktur und Dynamik von makromolekularen Systemen Untersuchung der molekularen und kollektiven Dynamik von Polymersystemen Transportphänomene im glasartigen Zustand Organisationsverhalten und Dynamik von Block-Copolymeren Eigenschaften von synthetischen und natürlichen Polyelektrolyten Entwicklung und Optimierung von experimentellen und theoretischen Methoden zur Polymercharakterisierung Festkörper-Kernresonanz-Spektroskopie Elektronen-Spin-Resonanz-Spektroskopie Massenspektrometrie Optik nicht-linearer Eigenschaften Oberflächen-Plasmonen-Optik Raster-Sonden-Mikroskopie, Röntgen- und Lichtstreuung Rheologie Computersimulationen der Statik und Dynamik von Schmelzen, Netzwerken, Mischungen und des Aggregationsverhaltens analytische Theorie auf der Grundlage der statistischen Mechanik numerische Computersimulation Messung von Oberflächenkräften Oberflächen- und Grenzflächeneigenschaften von Polymeren Charakterisierung von Makromolekülen an Oberflächen und Grenzflächen Wechselwirkung von Makromolekülen mit anderen Materialien Molekulare Erkennung Verbundwerkstoffe Adhäsion Nanotechnologie
Molekulare Elektronik, Direktor: Paul Blom Molekulare Spektroskopie, Direktor: Mischa Bonn Physik der Grenzflächen, Direktor: Hans-Jürgen Butt Biomolekulare Mechanik, Direktorin: Frauke Gräter Physikalische Chemie der Polymere, Direktorin: Katharina Landfester Synthese von Makromolekülen, Direktorin: Tanja Weil
== Emeriti und ehemalige Direktoren == Emeriti Polymerspektroskopie, Direktor 1985–2012: Hans Wolfgang Spiess Festkörperchemie, Direktor 1983–2008: Gerhard Wegner Theorie der Polymere, Direktor: Kurt Kremer Ehemalige Direktoren Physik der Polymere, Direktor 1983–1997: Erhard W. Fischer Materialwissenschaft, Direktor 1993–2008: Wolfgang Knoll Synthetische Chemie, Direktor: 1989–2016: Klaus Müllen
Sources: de.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.